Pay in 4 interest-free payments of $8.75 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
the combination of Dasatinib and GNF-2 overcame resistance of BCR/ABL-T315I in all models used in a synergistic manner
GSK0660 blocks the TNFα-induced upregulation of CCL8
InChi: InChI=1S/C18H18N2O3/c1-11(2)18(22)20-16(14-6-4-10-23-14)13-8-7-12-5-3-9-19-15(12)17(13)21/h3-11
InChi: InChI=1S/C24H32N6O3/c1-3-25-24(31)26-18-6-4-17(5-7-18)22-27-21-12-29(19-14-33-15-19)9-8-20(21)23(28-22)30-10-11-32-13-16(30)2/h4-7
PubMed PMID: 12723461
NLG919 (RG6078) - IDO Inhibitor. CAS# 1402836-58-1 0172 the combination of Dasatinib andNLG919, CAS No. 1402836 58 1, is a potent, selective and orally bioavailable IDO (indoleamine (2, 3) dioxygenase) pathway inhibitor with Ki ~7 nM (EC50 ~75 nM) in vitro and in cell based assays. Oral administration of NLG919 reduces the [Kyn] in plasma and tissue by ~ 50%. Using human IDO+ pDCs in allogeneic MLR reactions, NLG919 potently blocked IDO induced T cell suppression and restored robust T cell responses with an EC50 ~90 nM. NLG919 abrogated